Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fogel

Showing results (181-190 of 203) with videos related to

Pageof 21
Sort By:
Journal of the International AIDS Society|February 20, 2020
Determination of HIV status and identification of incident HIV infections in a large, community-randomized trial: HPTN 071 (PopART)Susan H Eshleman, Estelle Piwowar-Manning, Ethan A Wilson, et al.
The Journal of Infectious Diseases|October 14, 2022
HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV PreventionSusan H Eshleman, Jessica M Fogel, Elias K Halvas, et al.
JAMA Network Open|February 5, 2026
Prevalence of Illicit Drug Detection in 5 US Cities Among Out-of-Treatment People Who Inject DrugsNabila El-Bassel, Steven Shoptaw, Timothy Skalland, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 5, 2013
Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infectionMark A Marzinke, William Clarke, Lei Wang, et al.
HIV Clinical Trials|April 9, 2014
Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screeningEstelle Piwowar-Manning, Jessica M Fogel, Oliver Laeyendecker, et al.
Plos One|October 11, 2019
HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074Philip J Palumbo, Yinfeng Zhang, Jessica M Fogel, et al.
Microbiology Spectrum|July 9, 2024
Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxisJessica M Fogel, Estelle Piwowar-Manning, Amber Moser, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 11, 2015
Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men: HIV Prevention Trials Network 061Iris Chen, Matthew B Connor, William Clarke, et al.
The New England Journal of Medicine|July 24, 2024
Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure ProphylaxisRaphael J Landovitz, Sinead Delany-Moretlwe, Jessica M Fogel, et al.
Plos Medicine|June 18, 2021
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trialConnie Celum, Sybil Hosek, Mandisa Tsholwana, et al.
Pageof 21

Showing results (181-190 of 203) with videos related to

Sort By:
Pageof 21
Journal of the International AIDS Society|February 20, 2020
Determination of HIV status and identification of incident HIV infections in a large, community-randomized trial: HPTN 071 (PopART)Susan H Eshleman, Estelle Piwowar-Manning, Ethan A Wilson, et al.
The Journal of Infectious Diseases|October 14, 2022
HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV PreventionSusan H Eshleman, Jessica M Fogel, Elias K Halvas, et al.
JAMA Network Open|February 5, 2026
Prevalence of Illicit Drug Detection in 5 US Cities Among Out-of-Treatment People Who Inject DrugsNabila El-Bassel, Steven Shoptaw, Timothy Skalland, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 5, 2013
Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infectionMark A Marzinke, William Clarke, Lei Wang, et al.
HIV Clinical Trials|April 9, 2014
Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screeningEstelle Piwowar-Manning, Jessica M Fogel, Oliver Laeyendecker, et al.
Plos One|October 11, 2019
HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074Philip J Palumbo, Yinfeng Zhang, Jessica M Fogel, et al.
Microbiology Spectrum|July 9, 2024
Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxisJessica M Fogel, Estelle Piwowar-Manning, Amber Moser, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 11, 2015
Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men: HIV Prevention Trials Network 061Iris Chen, Matthew B Connor, William Clarke, et al.
The New England Journal of Medicine|July 24, 2024
Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure ProphylaxisRaphael J Landovitz, Sinead Delany-Moretlwe, Jessica M Fogel, et al.
Plos Medicine|June 18, 2021
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trialConnie Celum, Sybil Hosek, Mandisa Tsholwana, et al.
Pageof 21